Table 1.
Baseline characteristics of the patients*.
| Median Age (min-max) | 57 (27-71) years |
|---|---|
| Gender, n (%) | |
| Male | 21 (63.6%) |
| Female | 12 (36.4%) |
| Time from HSCT to COVID-19 Median (min-max) | 868 (31-2368) days |
| Primary Disease (Requiring HSCT), n (%) | |
| MM | 9 (27.3%) |
| HL | 1 (3.0%) |
| NHL | 8 (24.2%) |
| AML | 5 (15.2%) |
| ALL | 3 (9.1%) |
| PID | 2 (6.1%) |
| MF | 1 (3.0%) |
| MDS | 3 (9.1%) |
| ITP | 1 (3.0%) |
| HSCT, n (%) | |
| AHSCT | 19 (57.6%) |
| Allo-HSCT | 14 (42.4%) |
| Uncontrolled Primary Disease, n (%) | 9 (27.3%) |
| Use of Immunosuppressive Drugs, n (%) (Calcineurin inhibitors) | 4 (12.1%) |
| Donor (n=14) | |
| Full matched donor, n (%) | 12 (83.3%) |
| Haploidentical, n (%) | 2 (16.7%) |
| GVHD, n (%) | 6 (18.2%) |
| Chronic Diseases, n (%) | |
| CAD | 4 (12.1 %) |
| CKD | 7 (21.2%) |
| HT | 8 (24.2 %) |
| COPD | 1 (3.0 %) |
| DM | 3 (9.1 %) |
| Non-hematologic malignancy | 2 (6.1 %) |
*MM: multiple myeloma, HL: hodgkin-lymphoma: NHL: nonhodgkin lymphoma, AML: acute myeloid leukemia, ALL: acute lymphoblastic leukemia, PID: primary immunodeficiency, MF: mycosis fungoides, MDS: myelodysplastic syndrome, ITP: immune thrombocytopenia, GVHD: graft versus host disease, CAD: coronary artery disease, CKD: chronic kidney disease, HT: hypertension, COPD: chronic obstructive pulmonary disease, DM: diabetes mellitus.